CGM: From Medical Infrastructure to Metabolic Insight
Continuous Glucose Monitoring (CGM) is no longer exclusively for insulin-treated patients; in 2026, it is a General-Purpose Health Tool.
Abbott & Dexcom Consumer Lines: At CES 2026, these giants repositioned CGMs like the Libre Assist and Stelo as "Metabolic Trackers" for high-performance athletes and the general population.
Visual "Glucose Load": New apps allow users to photograph a meal; the AI then predicts the glucose spike and suggests real-time physical interventions (e.g., a 10-minute walk) to blunt the impact.
Intradermal Sensors: Biolinq’s new sensor monitors muscle loss and protein intake alongside glucose, helping patients on GLP-1 therapies preserve lean body mass.
1 vue